Asian Tech Press (Jan 11) -- Biopharmaceutical company Merck said its HPV vaccine supply to China is growing year by year and will increase significantly in 2022.

Cervical cancer is currently the most likely cancer to be eliminated at the public health level through HPV integrated prevention and control measures. The Chinese public has seen strong demand for HPV vaccines in recent years.

Merck is also actively conducting clinical trials to expand the indications for the HPV vaccine in order to cover more age groups and populations and protect the health of the Chinese public.